Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC).

被引：0
|
作者：
Sun, Hui-Chuan
Zhu, Xiao-Dong
Wang, Kui
Xue, Hui
Yang, Ning
Yang, Ying-Cheng
Chen, Yong-Jun
Ye, Feng
Kuang, Ming
Shen, Shun-Li
Huang, Cheng
机构：
[1] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Shanghai, Peoples R China
[2] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Dept Liver Surg & Transplantat, Shanghai, Peoples R China
[3] Naval Med Univ, Dept Hepat Surg 2, Eastern Hepatobiliary Surg Hosp, Affiliated Hosp 3, Shanghai, Peoples R China
[4] Naval Med Univ, Dept Hepat Surg 5, Affiliated Hosp 3, Eastern Hepatobiliary Surg Hosp, Shanghai, Peoples R China
[5] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Gen Surg, Sch Med, Shanghai, Peoples R China
[6] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Hepatopancreatobiliary Surg, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4120
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Adjuvant lenvatinib after radical resection in patients with hepatocellular carcinoma (HCC): Preliminary analysis of a prospective, multi-center, single-arm study.
    Zhou, Jian
    Sun, Hui-Chuan
    Huang, Zhi-Yong
    Liu, Lianxin
    Wen, Tianfu
    Zhu, Xiao-Dong
    Shi, Yinghong
    Gao, Qiang
    Qiu, Shuang-Jian
    Ding, Zhenbin
    Wang, Zheng
    Ye, Qing-Hai
    Huang, Xiao-Wu
    Huang, Cheng
    Peng, Yuan-Fei
    Shi, Guoming
    Wang, Xiao-Ying
    Fan, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16158 - E16158
  • [2] A prospective, single-arm, phase II clinical study of tislelizumab in combination with lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with high risk of recurrence.
    Song, Tianqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
    Xia, Yongxiang
    Tang, Weiwei
    Qian, Xiaofeng
    Li, Xiangcheng
    Cheng, Feng
    Wang, Ke
    Zhang, Feng
    Zhang, Chuanyong
    Li, Donghua
    Song, Jinhua
    Zhang, Hui
    Zhao, Jie
    Yao, Aihua
    Wu, Xiaofeng
    Wu, Chen
    Ji, Guwei
    Liu, Xisheng
    Zhu, Feipeng
    Qin, Lang
    Xiao, Xuan
    Deng, Zhenhua
    Kong, Xiangyi
    Li, Si
    Yu, Yangyang
    Xi, Wenjing
    Deng, Wanglong
    Qi, Chuang
    Liu, Hanyuan
    Pu, Liyong
    Wang, Ping
    Wang, Xuehao
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)
  • [4] Perioperative lenvatinib combined with tislelizumab plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase 2 trial.
    Wu, Jia-Yi
    Fu, Yang-Kai
    Wen, Tianfu
    Wang, Shuang-Jia
    Chen, Jiafei
    Zhang, Zhibo
    Liu, Chongyuan
    Wang, Wei
    Fang, Lu
    Tang, Zhong
    Chen, Yufeng
    Yan, Maolin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 503 - 503
  • [5] Neoadjuvant tislelizumab combined with lenvatinib plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence: A prospective, single-arm, phase II trial
    Chen, Zhiyu
    Zhang, Leida
    Zhang, Hui
    Gong, Yi
    Feng, Kai
    Ma, Kuansheng
    Bi, Huaqiang
    Xia, Feng
    Dai, Haisu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Efficacy of Shipixiaoji Granules, Lenvatinib, and Tislelizumab in Patients with Unresectable Hepatocellular Carcinoma: Protocol for a Prospective, Single-Arm, Phase II Trial
    Zhang, Zhen
    Liang, Zicheng
    Tan, Xiaoning
    Jian, Huiying
    Gao, Wenhui
    Zeng, Puhua
    NATURAL PRODUCT COMMUNICATIONS, 2024, 19 (12)
  • [7] Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Single-Arm, Phase II Multi-Center Trial
    Park, S.
    Ahn, H. K.
    Lee, S.
    Min, Y. J.
    Jung, H. A.
    Sun, J. -M.
    Lee, S-H.
    Ahn, J. S.
    Ahn, M. -J.
    Lee, J. B.
    Kim, S. M.
    Kim, H. R.
    Cho, B. C.
    Hong, M. H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S148 - S149
  • [8] Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
    Marron, Thomas U.
    Fiel, Maria Isabel
    Hamon, Pauline
    Fiaschi, Nathalie
    Kim, Edward
    Ward, Stephen C.
    Zhao, Zhen
    Kim, Joel
    Kennedy, Paul
    Gunasekaran, Ganesh
    Tabrizian, Parissa
    Doroshow, Deborah
    Legg, Meredith
    Hammad, Ashley
    Magen, Assaf
    Kamphorst, Alice O.
    Shareef, Muhammed
    Gupta, Namita T.
    Deering, Raquel
    Wang, Wei
    Wang, Fang
    Thanigaimani, Pradeep
    Mani, Jayakumar
    Troncoso, Leanna
    Tabachnikova, Alexandra
    Chang, Christie
    Akturk, Guray
    Buckup, Mark
    Hamel, Steven
    Ioannou, Giorgio
    Hennequin, Clotilde
    Jamal, Hajra
    Brown, Haley
    Bonaccorso, Antoinette
    Labow, Daniel
    Sarpel, Umut
    Rosenbloom, Talia
    Sung, Max W.
    Kou, Baijun
    Li, Siyu
    Jankovic, Vladimir
    James, Nicola
    Ham, Sara C.
    Cheung, Hung Kam
    Sims, Jennifer S.
    Miller, Elizabeth
    Bhardwaj, Nina
    Thurston, Gavin
    Lowy, Israel
    Gnjatic, Sacha
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (03): : 219 - 229
  • [9] Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma: A single-center, prospective, single-arm clinical trial
    Ren, Yupeng
    Li, Yuxuan
    Cao, Mingbo
    Tang, Yongchang
    Yuan, Feng
    Yang, Gaoyuan
    He, Zhiwei
    Shi, Zheng
    Su, Xiaorui
    Yao, Zhicheng
    Deng, Meihai
    CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (02)
  • [10] Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma:A single-center, prospective,single-arm clinical trial
    Yupeng Ren
    Yuxuan Li
    Mingbo Cao
    Yongchang Tang
    Feng Yuan
    Gaoyuan Yang
    Zhiwei He
    Zheng Shi
    Xiaorui Su
    Zhicheng Yao
    Meihai Deng
    Chinese Journal of Cancer Research, 2024, 36 (02) : 114 - 123
12345